National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Blinatumomab (Blincyto®)

Blincyto® is indicated for the treatment of adults with Philadelphia chromosome negative (Ph-) relapsed or refractory
B-precursor acute lymphoblastic leukaemia.

NCPE Assessment Process Completed
Rapid review received 08/12/2015
Rapid review completed 22/12/2015
Rapid Review outcome Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo® at this point in time.
Following submission of new evidence Full Pharmacoeconomic Evaluation Recommended.
Full pharmacoeconomic assessment commissioned by HSE 11/04/2017
Pre-submission consultation with Applicant 27/06/2017
Anticipated date of submission July 2017
Submission received from applicant 30/08/2017
Preliminary review sent to applicant 05/12/2017
NCPE assessment re-commenced 08/02/2018
Factual accuracy sent to Applicant 16/03/2018
NCPE assessment re-commenced 10/04/2018
NCPE assessment completed 16/04/2018
Full pharmacoeconomic assessment outcome The NCPE recommends that blinatumomab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013


The HSE has approved reimbursement following confidential price negotiations; May 2019